Objective To analyze the clinical efficacy of transarterial chemoembolization(TACE)combined with liver cell-targeted immunity on primary massive hepatocellular carcinomas.Methods A total of 300 patients with primary giant hepatocellular carcinomas admitted to 980th Hospital of PLA from December 2020 to December 2022 were selected as the study subjects.They were randomly assigned into the study group(TACE combined with liver cell-targeted immunotherapy,n=196)and the control group(TACE combined with targeted medication,n=104).The tumor diameter,disease response,tumor marker levels,incidence of adverse events,and prognosis were compared between two groups after treatment.Results There was no significant difference in tumor diameter between groups before treatment.After 1 month of treatment,the average tumor diameter of the study group was significantly smaller than that of the control group(6.3cm vs 8.8cm,P＜0.05).The objective response rate(ORR,54.08％vs 26.92％)and disease control rate(DCR,94.89％vs 80.77％)in the study group were significantly higher than those the control group(P＜0.05).The 6-month(81.12％vs 49.04％),12-month(62.76％vs 36.54％)and 18-month survival rates(44.39％vs 20.19％)of the study group were significantly higher than those of the control group(all P＜0.05).There was no significant difference in the total incidence of adverse events,such as abnormal liver function,abnormal renal function,and gastrointestinal reactions between groups after treatment(P＞0.05).Conclusion TACE combined with liver cell-targeted immunotherapy can reduce tumor diameter,alleviate symptoms,lower tumor marker levels,and improve prognosis of primary massive hepatocellular carcinomas,without significantly increasing the incidence of adverse events.It is worthy of clinical promotion and application.
维普
万方数据